Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3823 Added value of post 177Lu Dotatate and Ga PET/CT imaging in prediction and evaluation of treatment response for GEP NETs

Introduction: Theragnostic approach using 68Ga Dota-peptides (PET) for diagnosis and Lutetium-177 Dotatate (Lutate) for therapy is approved in gastroenteropancreatic neuroendocrine tumors (GEP-NET). The 24-hour post-Lutate treatment imaging (Lutate post tp) evaluates the radiotracer distribution.

Conference:

Presenting Author: Abenavoli E

Authors: Abenavoli E, Linguanti F, Briganti V, Antonuzzo L, Mungai F,

Keywords: Lutetium-177 Dotatate, 68Ga-Dota peptide, evaluation response, prediction response, imaging parameter,

#3822 68Ga-DOTA peptides PET/CT radiomics in differentiation between pancreatic NET from physiologic uncinate process uptake

Introduction: 68Ga-DOTA peptides PET/CT (PET/CT) is the gold standard for neuroendocrine tumors detection (NET), which are often localized in the pancreas. Physiological uptake of pancreatic uncinate process (UP) is a known false positive site in almost of patients.

Conference:

Presenting Author: Linguanti F

Authors: Linguanti F, Abenavoli E, Briganti V, Mungai F, Antonuzzo L,

Keywords: 68Ga-Dota peptide, PET/CT, pancreas, neuroendocrine tumor, pNET,

#1421 Oxaliplatin-based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors

Introduction: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Spada F

Authors: Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A,

Keywords: Oxaliplatin, NETs,

#1401 Everolimus (EV) Plus Somatostatin Analog (SSA) Administered Before or After Chemotherapy (CT) or PRRT in Advanced G1-G2 Neuroendocrine Tumor (NET): A Single Center Experience

Introduction: In metastatic NET G1-G2 progressed after SSA, many treatment are appropriated including EV, CT and PRRT. However, there are no studies guiding the appropriate sequence of treatments.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marconcini R

Authors: Marconcini R, Ricci S, Antonuzzo A, Luca G, Vasile E,

Keywords: everolimus SSA,

#1368 Everolimus in Pancreatic Neuroendocrine Carcinomas G3

Introduction: Neuroendocrine Carcinomas (NEC) G3 are heterogeneous diseases with different behaviors, basing on tumor morphology and Ki67 value. Platinum-based chemotherapy is considered the standard treatment in these pts. However, tumors with well-moderately differentiated morphology (NET G3), with Ki67 < 55% may be considered a separate entity in terms of prognosis and therapeutic options

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Panzuto F

Authors: Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T,

Keywords: Neuroendocrine carcinoma, everolimus,